- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefTM
- Patient Resources
Even when appearing relatively mild, hyponatremia can increase morbidity and mortality in different clinical scenarios. Hyponatremia has been shown to increase gait instability and falls leading to an increased risk of bone fractures. Join us for this webinar featuring Dr Joseph Verbalis, MD, Division Chief, Endocrinology & Metabolism, Director, Georgetown University Medical Center as we discuss the association between hyponatremia and falls and fractures.
*Dr Joseph Verbalis is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Geoff Lockwood is an employee of OPDC.
If you would like to register for the 6:00 pm to 7:00 pm EDT broadcast, please click below:
Georgetown University Medical Center*
Joseph G Verbalis, MD, graduated from Princeton University with an AB in chemistry in 1971, and received an MD from the University of Pittsburgh in 1975. He completed his residency training at the Hospital of the University of Pennsylvania from 1975-1978 and his fellowship training in endocrinology and metabolism at the University of Pittsburgh from 1978-1980. Dr Verbalis was a faculty member at the University of Pittsburgh from 1980 through 1995 where he rose to the position of tenured Professor of Medicine, and then relocated to Georgetown University in Washington, DC where he has served as the Chief of the Division of Endocrinology and Metabolism since 1995. Dr Verbalis’ research has been continuously funded by the NIH for 25 years and has concentrated on mechanisms underlying adaptation to hyponatremia, renal escape from vasopressin, osmotic regulation of hypothalamic gene expression, sex differences in physiology and pathophysiology, exercise-associated hyponatremia, hyponatremia-induced osteoporosis, and clinical use of vasopressin receptor antagonists. He has published over 300 journal articles, reviews, and book chapters related to the neuroendocrine regulation of vasopressin and oxytocin, and disorders of body fluid homeostasis (h-index=75). He authors the chapters on vasopressin and water metabolism in major textbooks of endocrinology, nephrology, and neuroscience. He is a regular speaker at national and international meetings on neuroendocrinology and body fluid homeostasis, with invited lectureships in 35 states and 36 countries.
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Geoffrey Lockwood, PharmD, BCPS, MBA is a clinical pharmacist who works as a Medical Science Liaison with Otsuka Pharmaceutical Development & Commercialization, Inc. He has been in his current role for 2 years, supporting Nephrology. Prior to joining Otsuka, he worked as an Emergency Medicine and Critical Care Clinical Pharmacist at Spectrum Health Butterworth Hospital in Grand Rapids, Michigan. Dr Lockwood earned his Doctor of Pharmacy Degree from Ferris State University in Big Rapids, Michigan. Dr Lockwood completed a PGY-1 Pharmacy Practice Residency with Christus Spohn Health System in Corpus Christi, Texas. Upon completion of residency, Dr. Lockwood worked as a Critical Care Clinical Pharmacy Specialist with Christus Spohn Memorial Hospital in Corpus Christi, Texas. He then moved to South Bend, Indiana where he took on the role of Clinical Pharmacy and Pharmacy Residency Program Coordinator at Memorial Hospital of South Bend. Dr Lockwood then moved to Elkhart General Hospital where he started the Emergency Medicine Clinical Pharmacy Program and served as an Emergency Medicine Clinical Pharmacy Specialist. Dr Lockwood is currently working to complete his MBA with a Value-Driven Organization emphasis through Central Michigan University. Dr Lockwood is board certified in pharmacotherapy and is a licensed pharmacist in the states of Michigan and Indiana.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.May 2020 MRC2.CORP.X.04767
January 31 from 12:00 pm to 1:00 pm
February 14 from 12:00 pm to 1:00 pm
- Resource Center
- Patient Resources